Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.5581 USD
−22.94 M USD
1.10 M USD
4.96 M
About Matinas Biopharma Holdings, Inc.
Sector
CEO
Jerome D. Jabbour
Headquarters
Bedminster
Website
Founded
2013
FIGI
BBG005WX2XG8
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MTNB is 0.5950 USD — it has increased by 10.16% in the past 24 hours. Watch Matinas Biopharma Holdings, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Matinas Biopharma Holdings, Inc. stocks are traded under the ticker MTNB.
MTNB stock has fallen by −0.63% compared to the previous week, the month change is a −5.56% fall, over the last year Matinas Biopharma Holdings, Inc. has showed a −95.14% decrease.
MTNB reached its all-time high on Mar 2, 2017 with the price of 199.5000 USD, and its all-time low was 0.5000 USD and was reached on Nov 6, 2024. View more price dynamics on MTNB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MTNB stock is 17.45% volatile and has beta coefficient of 3.36. Track Matinas Biopharma Holdings, Inc. stock price on the chart and check out the list of the most volatile stocks — is Matinas Biopharma Holdings, Inc. there?
Today Matinas Biopharma Holdings, Inc. has the market capitalization of 2.75 M, it has decreased by −6.98% over the last week.
Yes, you can track Matinas Biopharma Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Matinas Biopharma Holdings, Inc. is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
MTNB earnings for the last quarter are −0.85 USD per share, whereas the estimation was −1.05 USD resulting in a 19.43% surprise. The estimated earnings for the next quarter are −0.78 USD per share. See more details about Matinas Biopharma Holdings, Inc. earnings.
Matinas Biopharma Holdings, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MTNB net income for the last quarter is −4.28 M USD, while the quarter before that showed −5.72 M USD of net income which accounts for 25.25% change. Track more Matinas Biopharma Holdings, Inc. financial stats to get the full picture.
No, MTNB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 32.00 employees. See our rating of the largest employees — is Matinas Biopharma Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Matinas Biopharma Holdings, Inc. EBITDA is −21.05 M USD, and current EBITDA margin is −2.08 K%. See more stats in Matinas Biopharma Holdings, Inc. financial statements.
Like other stocks, MTNB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Matinas Biopharma Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Matinas Biopharma Holdings, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Matinas Biopharma Holdings, Inc. stock shows the sell signal. See more of Matinas Biopharma Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.